AbCellera Biologics (ABCL) Financial Statements & Analysis

AbCellera Biologics (ABCL) Income Statement

AbCellera Biologics reported revenue of $75.13M in fiscal 2025 (fiscal year ended Dec 31, 2025), up 160.6% from $28.83M a year earlier. AbCellera Biologics posted a net loss of $146.41M, compared with a net loss of $162.86M a year earlier. Gross margin was 61.6% and operating margin -289.0%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $4.05M, down 76.3% from the same quarter a year earlier.

AbCellera Biologics Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

AbCellera Biologics Inc. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018
Revenue & Gross Profit
Revenue	75.13	28.83	38.03	485.42	375.20	233.16	11.61	8.83
Cost of Revenue	28.82	167.26	0.00	66.44	107.58	27.14	0.00	0.00
Gross Profit	46.31	28.83	38.03	418.99	375.20	206.01	11.61	8.83
Operating Expenses
Research & Development	186.83	167.26	175.66	107.88	62.06	29.39	10.11	5.80
Selling, General & Administrative	76.58	85.49	75.18	66.76	48.76	15.75	4.01	2.86
Operating Expenses	263.41	329.98	275.23	202.48	170.79	49.98	15.73	9.58
Operating Income	-217.10	-301.15	-237.21	216.51	204.41	156.03	-4.12	-0.75
Other Income/Expense
Interest Income	28.33	38.47	42.25	16.08	3.33	0.29	0.16	0.04
Interest Expense	0.00	0.00	0.00	4.05	5.23	6.51	0.21	0.21
Other Income/Expense	39.51	62.28	63.18	22.59	14.74	1.80	1.91	1.06
Income
Income Before Tax	-177.60	-200.40	-174.03	239.10	219.15	157.83	-2.21	0.31
Income Tax Expense	-31.18	-37.54	-27.63	80.58	65.69	38.92	0.00	0.00
Net Income	-146.41	-162.86	-146.40	158.52	153.46	118.92	-2.21	0.31
Net Income - Continuous Operations	-146.41	-162.86	-146.40	158.52	153.46	118.92	-2.21	0.31
Net Income - Discontinued Operations	-	-	-	-	-	-	-	-
EBITDA	-148.77	-204.15	-192.16	260.17	218.88	169.62	-0.16	1.44
EBIT	-203.21	-301.15	-223.05	227.07	204.41	156.03	-	-
Depreciation & Amortization	28.82	90.85	30.89	33.10	14.47	5.27	1.85	0.92
Earnings Per Share
Basic EPS	-	-1.00	-1.00	1.00	1.00	-	-	-
Diluted EPS	-	-1.00	-1.00	1.00	-	-	-	-
Basic Shares Outstanding	298.71	294.33	289.17	285.06	275.76	263.13	215.41	151.04
Diluted Shares Outstanding	298.71	294.33	289.17	314.83	318.29	263.13	237.72	151.04

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About AbCellera Biologics Financial Statements

What was AbCellera Biologics's revenue in fiscal 2025?

AbCellera Biologics reported revenue of $75.13M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was up 160.6% from $28.83M a year earlier.

Is AbCellera Biologics profitable?

No. AbCellera Biologics reported a net loss of $146.41M in fiscal 2025. In fiscal 2024 it lost $162.86M.

What is AbCellera Biologics's operating margin?

AbCellera Biologics's operating income was −$217.10M on revenue of $75.13M in fiscal 2025, an operating margin of -289.0%, compared with -1044.4% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition